Mutations to bid cleavage sites protect hepatocytes from apoptosis after ischemia/reperfusion injury

Transplantation

Volumn 84, Issue 6, 2007, Pages 778-785

  Riddle Taylor, Erica ^a   Nagasaki, Kazuhito ^a   Lopez, Joseph ^a   Esquivel, Carlos O ^a   Martinez, Olivia M ^a   Krams, Sheri M ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MSLS P313 ^*  (United States)

Author keywords

Apoptosis; Bid; Liver

Indexed keywords

ASPARTIC ACID; CASPASE 8; GLUTAMIC ACID; GRANZYME B; MUTANT PROTEIN; PROTEIN BID;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; DNA CLEAVAGE; ENZYME ACTIVATION; GENETIC TRANSDUCTION; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL; LIVER FUNCTION; LIVER ISCHEMIA; MEMBRANE DAMAGE; MITOCHONDRIAL MEMBRANE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REPERFUSION INJURY; SURVIVAL RATE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; APOPTOSIS; ASPARTIC ACID; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CASPASE 8; GLUTAMIC ACID; GRANZYMES; HEPATOCYTES; MOLECULAR SEQUENCE DATA; MUTATION; RATS; RATS, WISTAR; REPERFUSION INJURY;

EID: 34748912344     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000281555.18782.2b     Document Type: Article

References (41)

1. Malhi H, Gores GJ, Lemasters JJ. Apoptosis and necrosis in the liver: A tale of two deaths? Hepatology 2006; 43: S31.
2. Yin XM, Ding WX. Death receptor activation-induced hepatocyte apoptosis and liver injury. Curr Mol Med 2003; 3: 491.
3. Guicciardi ME, Gores GJ. Apoptosis: A mechanism of acute and chronic liver injury. Gut 2005; 54: 1024.
4. Terradillos O, de La Coste A, Pollicino T, et al. The hepatitis B virus X protein abrogates Bcl-2-mediated protection against Fas apoptosis in the liver. Oncogene 2002; 21: 377.
5. Kohli V, Selzner M, Madden JF, et al. Endothelial cell and hepatocyte deaths occur by apoptosis after ischemia-reperfusion injury in the rat liver. Transplantation 1999; 67: 1099.
6. Krams SM, Egawa H, Quinn MB, et al. Apoptosis as a mechanism of cell death in liver allograft rejection. Transplantation 1995; 59: 621.
7. Faubion WA, Guicciardi ME, Miyoshi H, et al. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J Clin Invest 1999; 103: 137.
8. Boatright KM, Salvesen GS. Mechanisms of caspase activation. Curr Opin Cell Biol 2003; 15: 725.
9. Li S, Zhao Y, He X, et al. Relief of extrinsic pathway inhibition by the Bid-dependent mitochondrial release of Smac in Fas-mediated hepatocyte apoptosis. J Biol Chem 2002; 277: 26912.
10. Barnhart BC, Alappat EC, Peter ME. The CD95 type I/type II model. Semin Immunol 2003; 15: 185.
11. Esposti MD. The roles of Bid. Apoptosis 2002; 7: 433.
12. Gross A, Yin XM, Wang K, et al. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem 1999; 274: 1156.
13. Luo X, Budihardjo I, Zou H, et al. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998; 94: 481.
14. Lutter M, Fang M, Luo X, et al. Cardiolipin provides specificity for targeting of tBid to mitochondria. Nat Cell Biol 2000; 2: 754.
15. Sharpe JC, Arnoult D, Youle RJ. Control of mitochondrial permeability by Bcl-2 family members. Biochim Biophys Acta 2004; 1644: 107.
16. Korsmeyer SJ, Wei MC, Saito M, et al. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ 2000; 7: 1166.
17. Hajra KM, Liu JR. Apoptosome dysfunction in human cancer. Apoptosis 2004; 9: 691.
18. Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 2004; 5: 897.
19. Yin XM, Wang K, Gross A, et al. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 1999; 400: 886.
20. Kuo CJ, Farnebo F, Yu EY, et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci USA 2001; 98: 4605.
21. Chartier C, Degryse E, Gantzer M, et al. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 1996; 70: 4805.
22. Bayly AC, French NJ, Dive C, Roberts RA. Non-genotoxic hepatocarcinogenesis in vitro: The FaO hepatoma line responds to peroxisome proliferators and retains the ability to undergo apoptosis. J Cell Sci 1993; 104: 307.
23. Kim JH, Yamaguchi K, Lee SH, et al. Evaluation of polycyclic aromatic hydrocarbons in the activation of early growth response-1 and peroxisome proliferator activated receptors. Toxicol Sci 2005; 85: 585.
24. Kim BC, Kim HT, Mamura M, et al. Tumor necrosis factor induces apoptosis in hepatoma cells by increasing Ca(2+) release from the endoplasmic reticulum and suppressing Bcl-2 expression. J Biol Chem 2002; 277: 31381.
25. Matzinger P. The JAM test. A simple assay for DNA fragmentation and cell death. J Immunol Methods 1991; 145: 185.
26. Huguet C, Addario-Chieco P, Gavelli A, et al. Technique of hepatic vascular exclusion for extensive liver resection. Am J Surg 1992; 163: 602.
27. Ding WX, Ni HM, DiFrancesca D, et al. Bid-dependent generation of oxygen radicals promotes death receptor activation-induced apoptosis in murine hepatocytes. Hepatology 2004; 40: 403.
28. Werner AB, Tait SW, de Vries E, et al. Requirement for aspartate-cleaved bid in apoptosis signaling by DNA-damaging anti-cancer regimens. J Biol Chem 2004; 279: 28771.
29. Sutton VR, Davis JE, Cancilla M, et al. Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation. J Exp Med 2000; 192: 1403.
30. Wiltrout RH. Regulation and antimetastatic functions of liver-associated natural killer cells. Immunol Rev 2000; 174: 63.
31. Obara H, Nagasaki K, Hsieh CL, et al. IFN-gamma, produced by NK cells that infiltrate liver allografts early after transplantation, links the innate and adaptive immune responses. Am J Transplant 2005; 5: 2094.
32. Loh J, Chu DT, O'Guin AK, et al. Natural killer cells utilize both perforin and gamma interferon to regulate murine cytomegalovirus infection in the spleen and liver. J Virol 2005; 79: 661.
33. Chen Y, Wei H, Gao B, et al. Activation and function of hepatic NK cells in hepatitis B infection: An underinvestigated innate immune response. J Viral Hepat 2005; 12: 38.
34. Hsieh CL, Ogura Y, Obara H, et al. Identification, cloning, and characterization of a novel rat natural killer receptor, RNKP30: A molecule expressed in liver allografts. Transplantation 2004; 77: 121.
35. Cursio R, Gugenheim J, Ricci JE, et al. A caspase inhibitor fully protects rats against lethal normothermic liver ischemia by inhibition of liver apoptosis. Faseb J 1999; 13: 253.
36. Bilbao G, Contreras JL, Gomez-Navarro J, et al. Genetic modification of liver grafts with an adenoviral vector encoding the Bcl-2 gene improves organ preservation. Transplantation 1999; 67: 775.
37. Hoglen NC, Anselmo DM, Katori M, et al. A caspase inhibitor, IDN-6556, ameliorates early hepatic injury in an ex vivo rat model of warm and cold ischemia. Liver Transpl 2007; 13: 361.
38. Baskin-Bey ES, Washburn K, Feng S, et al. Clinical Trial of the Pan-Caspase Inhibitor, IDN-6556, in Human Liver Preservation Injury. Am J Transplant 2007; 7: 218.
39. McDonnell JM, Fushman D, Milliman CL, et al. Solution structure of the proapoptotic molecule BID: A structural basis for apoptotic agonists and antagonists. Cell 1999; 96: 625.
40. Kakimi K, Lane TE, Wieland S, et al. Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J Exp Med 2001; 194: 1755.
41. Reddy S, Zilvetti M, Brockmann J, et al. Liver transplantation from non-heart-beating donors: Current status and future prospects. Liver Transpl 2004; 10: 1223.